# Personalized Immunotherapeutic for Antibiotic-resistant Infection

> **NCT02508584** · EARLY_PHASE1 · COMPLETED · sponsor: **Brigham and Women's Hospital** · enrollment: 1 (actual)

## Conditions studied

- Infection
- Immune Deficiency
- Hypogammaglobulinemia
- Septic Arthritis
- Mycoplasma Hominis

## Interventions

- **BIOLOGICAL:** anti-mycoplasma hominis antibodies

## Key facts

- **NCT ID:** NCT02508584
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-12
- **Primary completion:** 2019-06-12
- **Final completion:** 2019-06-12
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2020-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02508584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02508584, "Personalized Immunotherapeutic for Antibiotic-resistant Infection". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02508584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*